Navigation Links
BioMS Medical to present at BIO CEO and Investor Conference
Date:2/5/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO & Investor Conference in New York.

    WHEN:     Monday February 9th at 2:45pm (Eastern Time)

    WHERE:    Waldorf-Astoria, New York City


    About BIO CEO & Investor Conference
    -----------------------------------
    This conference aims to bring together institutional investors, industry
analysts, and senior biotechnology executives in a neutral and collaborative
forum to examine investment opportunities and issues affecting the industry.
For more information visithttp://ceo.bio.org/opencms/ceo/2009/index.jsp.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that ma
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
2. BioMS Medical recognized at Scrip Awards 2008
3. BioMS Medical Announces Third Quarter 2008 Results
4. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
8. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
9. BioMS Medical to present at UBS Global Life Sciences Conference
10. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
(Date:7/24/2014)... 24, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the Company will ... 30, 2014 on Monday, August 18, 2014 for shareholders. ... ET on Monday, August 18, 2014 to discuss the ... company,s CEO, Anthony Hayes . Following ...
(Date:7/24/2014)... 24, 2014 As part of the ... in the MENA region during 2014 with potential global ... provider agreement with DZS to manage our clinical trials ... Global VP of R&D and President of SBI pharmaceuticals ... operational practices with a focus on utilizing eClinical software ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") ... in a Phase 1b clinical trial of PX-12 ... proprietary small molecule,inhibitor of thioredoxin, a protein that ... survival and drug resistance of,many cancers., The ...
... and present a poster on proprietary siRNA ... targeting and ... Pharmaceuticals, Inc., a,development-stage pharmaceutical company discovering and developing novel,RNA ... Cambridge Healthcare Institute,s 9th Annual Beyond,Genome Conference on June ...
... Calif., June 10 DURECT Corporation,(Nasdaq: DRRX ... (NDA) for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to ... investigational drug, is a long,acting oral formulation of ... on DURECT,s ORADUR technology, Remoxy is designed to ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 2Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5
(Date:7/24/2014)... This news release is available in German . ... that there are 300 million asthma sufferers worldwide, a ... up to 30% of the global population contending with ... inflammatory diseases can also affect other organs and parts ... occur in the intestine (in the form of inflammatory ...
(Date:7/24/2014)... news release is available in German . ... welcomed in Norway and they are a common sight on ... that electric cars topped the list of new vehicle registrations ... the situation in Germany, where electric vehicles claim only a ... on the roads in Germany, only a mere 8000 are ...
(Date:7/24/2014)... in German . ... respond to threats to health, and to provide life-long ... the mechanism underlying immunologic memory, however, has remained elusive. ... support the hypothesis that the persistence of immune memory ... potential. Until now, there was no conclusive evidence, largely ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3
... 2011 With millions of people warding off winter,s ... raising red flags about the potential health effects of ... in the American Chemical Society,s (ACS,) journal, Chemical ... inhaled into the lungs from wood smoke may have ...
... Darwin, the "tree of life" has been the preeminent metaphor ... changing of individual species. The discovery that a large ... species of fungus to another, however, significantly strengthens the argument ... more appropriate. "The fungi are telling us something important ...
... reports that family mealtimes that contain three ingredients in the ... who have chronic asthma. "Family mealtimes, when they,re done ... reduced risk of substance abuse, eating disorders, and obesity. In ... we can see minute by minute which factors deliver these ...
Cached Biology News:Discovery of jumping gene cluster tangles tree of life 2Discovery of jumping gene cluster tangles tree of life 3Recipe for family mealtimes calls for 3 ingredients in the right amounts 2
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Biology Products: